Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CA-125

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    159 result(s) found for: CA-125. Displaying page 6 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2022-003666-20 Sponsor Protocol Number: P1606-SUR-O25 Start Date*: 2023-05-09
    Sponsor Name:Immunovaccine Technologies Inc. (IMV Inc.)
    Full Title: Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects with Platinum-Resistant, Epithelial Ovarian Cancer (AVALON)
    Medical condition: Platinum Resistant Epithelial Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004850-14 Sponsor Protocol Number: GEICO-1601 Start Date*: 2017-11-13
    Sponsor Name:Grupo Español de Investigación en Cancer de Ovario
    Full Title: Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tu...
    Medical condition: Platinum resistant ovarian primary peritoneal carcinoma, and fallopian tube cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004682-40 Sponsor Protocol Number: CBYL719K12301 Start Date*: 2021-06-16
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single a...
    Medical condition: Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) PT (Completed) FI (Trial now transitioned) CZ (Completed) DK (Completed) SK (Completed) FR (Completed) NL (Completed) ES (Ongoing) DE (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002296-18 Sponsor Protocol Number: CaTo-ROC Start Date*: 2015-07-30
    Sponsor Name:Vejle Hospital, Department of Oncology
    Full Title: Cabazitaxel in patients with Recurrent Ovarian Cancer after failure of standard therapy- A phase II trial
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002803-13 Sponsor Protocol Number: 1775-004 Start Date*: 2012-04-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Phase II Study Evaluating MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian C...
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SE (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004332-36 Sponsor Protocol Number: DTX-SPL8783-002 Start Date*: 2020-02-01
    Sponsor Name:Starpharma Pty Ltd
    Full Title: A Phase 1/2 Modular, Multi-Arm Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of DTX-SPL8783 (DEP docetaxel/DEP-DTX) in Combination with Anti-Cancer Treatments, in Patients wit...
    Medical condition: Advanced malignant solid tumours
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-003883-31 Sponsor Protocol Number: GEICO-1205 Start Date*: 2013-04-02
    Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario
    Full Title: A randomized phase II multi-centric open label clinical trial to determine the efficacy and toxicity of preoperative chemotherapy with or without bevacizumab in patients with advanced Ovarian Cancer.
    Medical condition: Advanced Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004858-18 Sponsor Protocol Number: Toco-Ovar Start Date*: 2014-12-19
    Sponsor Name:Vejle Hospital
    Full Title: Tocotrienol as a nutritional supplement in patients with advanced ovarian cancer
    Medical condition: Chemotherapy resistant ovarian cancer with progressive disease.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004364-11 Sponsor Protocol Number: 69HCL15_0321 Start Date*: 2016-03-07
    Sponsor Name:Hospices Civils de Lyon
    Full Title: ENDOLA A PHASE I/II TRIAL TO ASSESS THE SAFETY AND EFFICACY OF METRONOMIC CYCLOPHOSPHAMIDE, METFORMIN AND OLAPARIB IN RECURRENT ADVANCED/METASTATIC ENDOMETRIAL CANCER PATIENTS
    Medical condition: - Patients with histologically and/or cytologically documented endometrial carcinoma (type I or type II), recurrent after platinum-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018478-19 Sponsor Protocol Number: GEICO-1001 Start Date*: 2010-06-07
    Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario - GEICO
    Full Title: Ensayo fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidación en pacientes con un cáncer epitelial de ovario en una segunda o tercera remisión completa
    Medical condition: eficacia y seguridad de catumaxomab como tratamiento de consolidación en pacientes con un cáncer epitelial de ovario en una segunda o tercera remisión completa
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004020-21 Sponsor Protocol Number: PR-Trab-PT Start Date*: 2015-04-01
    Sponsor Name:Fundación para la investigación biomédica del Hospital Clínico San Carlos
    Full Title: Reintroduction of platinum-based therapy after treatment with trabectedin in patients with relapsed ovarian cancer resistant to platinum
    Medical condition: Ovarian cancer resistant to the treatment with platinum
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005814-12 Sponsor Protocol Number: UCL10/0470 Start Date*: 2013-08-19
    Sponsor Name:University College London
    Full Title: Phase II, randomised, placebo controlled, multicentre, feasibility study of low dose (metronomic) cyclophosphamide with or without nintedanib (BIBF 1120) in advanced ovarian cancer (METRO-BIBF)
    Medical condition: Advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-006288-23 Sponsor Protocol Number: GINECO-OV-119 Start Date*: 2013-06-11
    Sponsor Name:ARCAGY
    Full Title: Randomized double blind placebo-controlled phase II trial of Vargatef® in addition to first line chemotherapy with interval debulking surgery in patients with adenocarcinoma of the ovary, the fallo...
    Medical condition: Patients with newly diagnosed FIGO stage IIIC - IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a carboplatin/paclitaxel chemotherapy fr...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004083-25 Sponsor Protocol Number: NOGGO-ov44 Start Date*: 2021-10-21
    Sponsor Name:NOGGO e.V.
    Full Title: Phase II investigational study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer
    Medical condition: platinum-sensitive recurrent low-grade serous ovarian cancer (including patients with primary peritoneal and / or fallopian tube adenocarcinoma)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002687-65 Sponsor Protocol Number: 2317 Start Date*: 2019-04-18
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: The NUVOLA TRIAL: Neoadjuvant chemoteraphy in Unresectable oVarian cancer with OLAparib and weekly carboplatin plus paclitaxel. A phase II open-label multi-centre study.
    Medical condition: ADVANCED OVARIAN CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054913 Serous cystadenocarcinoma ovary PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005504-13 Sponsor Protocol Number: 2006.444/37 Start Date*: 2007-03-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: ETUDE MULTICENTRIQUE FAG-3 : TRAITEMENT PAR CARBOPLATINE DES PATIENTES DE PLUS DE 70 ANS ATTEINTES DE CANCER AVANCE DE L’OVAIRE : PREDICTION DE LA VULNERABILITE INDIVIDUELLE PAR UNE EVALUATION PSY...
    Medical condition: cancer avancé de l'ovaire
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057529 Ovarian cancer metastatic LLT
    Population Age: Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000230-35 Sponsor Protocol Number: 014-FPO18 Start Date*: 2018-10-17
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS
    Full Title: Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced ...
    Medical condition: platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003166-39 Sponsor Protocol Number: ChImDLP-2 Start Date*: 2022-08-08
    Sponsor Name:UAB Froceth
    Full Title: A study of the safety of chemoimmunotherapy with autologous Dendritic Cell Preparations in patients with stage III ovarian cancer
    Medical condition: Stage III of high malignancy Ovarian serous adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000617-20 Sponsor Protocol Number: MITO31 Start Date*: 2018-11-14
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The MITO 31 transalational study.
    Medical condition: patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000987-14 Sponsor Protocol Number: TRAMANT-01 Start Date*: 2017-10-20
    Sponsor Name:AZIENDA OSPEDALIERA PER L'EMERGENZA CANNIZZARO
    Full Title: Phase II Study: Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovar...
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 04:35:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA